Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix.

NCT00946556 is registered in ClinicalTrials.gov with University of Toronto as lead sponsor.

NCT NCT00946556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00946556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix.
Lead sponsor
University of Toronto
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2010
Completion date
May 31, 2011
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes simplex type two infection, hiv infections